Clinical trials: Lean Body Mass
ER+ and AR+ Breast Cancer
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.
- Trial name
- NCT02746328
- Testing
- GTx-024 9 or 18 mg
- Where
- United States
- Sponsor
- GTx
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Wounds, Lean Body Mass
Amino Acid Usage Patterns in Daily Practice
The present study aims to evaluate the patient profile including medical conditions who use a nutritional supplement along with a balanced and varied diet in Turkey.
- Trial name
- NCT02146612
- Testing
- Amino Acid Supplement Group
- Where
- 18 sites in Turkey (Türkiye)
- Volunteers
- 354 people
- Sponsor
- Abbott Nutrition
Sarcopenia
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
- Trial name
- NCT02468674
- Testing
- bimagrumab
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Hypercatabolic Status Related to Severe Burn
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
- Trial name
- NCT02074995
- Testing
- BVS857
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Cachexia
Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioning and increased nutrition is not…
- Trial name
- VT-122 (NCT00527319)
- Testing
- VT-122 low dose, VT-122 high dose
- Where
- 8 sites in United States, India
- Volunteers
- 37 people
- Sponsor
- Vicus Therapeutics
Healthy
Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.
The study will evaluate the effects of oral nutritional supplements (ONS) on attenuating the lean body mass (LBM) loss that occurs after bed rest.
- Trial name
- NCT02090387
- Testing
- ONS without AN777, ONS containing AN777
- Where
- 3 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
- Trial name
- NCT02152761
- Testing
- bimagrumab
- Where
- 53 sites in United States, Argentina and 17 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Cancer Patients With Cachexia
Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer
The primary objectives of this study are to evaluate the effects of an amino acid mixture (Amixea) on the body composition as assessed by DXA, and on QMVC as assessed by strain gauge, in advanced NSCLC patients, compared to…
- Trial name
- NCT02877966
- Testing
- Amixea
- Where
- 3 sites in Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Helsinn Healthcare SA
Obesity & Overweight
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults
Muscle loss during caloric restriction is a significant concern for metabolic health and physical function, yet there is limited evidence on interventions that simultaneously target multiple contributing pathways.
- Trial name
- Redefine (NCT07447843)
- Testing
- Redefine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Nature's Sunshine Products, Inc.
Obesity
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®).
- Trial name
- COURAGE (NCT06299098)
- Testing
- Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals